Rome, 28 December – Aifa made available yesterday, 27 December, the documents on the monthly monitoring of national and regional pharmaceutical expenditure for the period January / August 2021, carried out on the basis of agreed expenditure data and summary accounting statements (Dc ) obtained from the Regions, as well as the data obtained from the new National Information System (NIS) of the Ministry of Health, on the traceability of the drug (Ministerial Decision of 15 July 2004).
The data from the last monitoring confirm situations and trends that seem to be more consolidated: at the national level, the total expenditures in the first 8 months of 2021 amounted to 12,957.3 million euros, showing an absolute deviation from the total resources of 14.85% (10,465 million). equal to about 997.3 million, which corresponds to a percentage of impact on the National Health Fund (Fsn) 16.09%.
The gap in the trend of direct purchases and subsidized expenditure is still strong: the first, continuing a trend consolidated in recent years, exceeds the expenditure ceiling of 1,361.6 million. On the other hand, the agreed territorial expenditures confirm the Its “virtuous course”, remaining below the ceiling of 383.6 million. With regard to roofs, it is worth recalling that in 2021 the new thresholds came into force (7% for land area, compared to 7.96% before and 7.65% for direct purchases, with an increase of almost one percentage point compared to the previous 6.69%). But these are values that are destined to change further with the new 2022 budget law.
Returning to the basics of monitoring, the NHS agreed on the estimated pharmaceutical costs without discounts, total tickets (regional and sharing at the reference price) and the 1.83% repayment paid to the Regions by the pharmaceutical companies, achieved during the period January -August 2021 the amount of 5,254.6 million euros affecting the National Health Fund by 6.52%, creating a surplus of 383.2 million euros. In this case, all the Regions except Basilicata, Calabria, Lombardy, Abruzzo, Puglia and Campania spent less than the expected expenditure ceiling.
A completely different story for pharmaceutical spending on direct purchases, which in the first eight months of 2021, clean of medical gases (7,522.8 million euros), recorded the aforementioned “passage” of 1,361.6 million euros against the ceiling of 7 , 65%. In this case, no Region has been able to comply with the expenditure ceiling, except in the Aosta Valley and Lombardy.
The monitoring revealed a small increase in consumption (+ 2.1%) compared to 2020, for a total of 363.7 million prescriptions. The number of daily installments distributed is slightly reduced by 0.2% (-34.2 million) and the frequency of the total ticket is still reduced (-5%) and that (minus 0.9%) related to the common cost from the citizens for the purchase of the price difference in the event of purchase of branded medicines ((710.1 million).
For the medicines included in the fund of innovative non-oncology medicines, the expenditure from January to August 2021, net of depreciation, was 163.1 million euros, while for the medicines included in the fund of innovative oncological medicines, Expenditure (again net depreciation) amounted to € 393.6 million.